PF-06747775 + palbociclib

PF-06747775 + palbociclib is an investigational oral combination therapy evaluated for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. PF-06747775 (also known as mavelertinib) is a third-generation EGFR tyrosine kinase inhibitor designed to target both activating and resistance mutations in EGFR, including T790M. Palbociclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression from G1 to S phase by inhibiting phosphorylation of the retinoblastoma protein. The combination aims to provide dual inhibition of tumor growth pathways—targeting both EGFR-driven signaling and cell cycle progression—to overcome resistance mechanisms in NSCLC after prior EGFR inhibitor therapy[1][3][5][7].

Brand names

Ibrance

Other names

PF-06747775 + palbociclibmavelertinib + palbociclib